Pricing Log in Create free account

Nurix Therapeutics, Inc. (NRIX) vs Zai Lab Limited Unsponsored ADR (ZLAB)

Nurix Therapeutics, Inc. and Zai Lab Limited Unsponsored ADR are both Biotechnology companies. Nurix Therapeutics, Inc. and Zai Lab Limited Unsponsored ADR are of similar size ($2.7B and $2.7B). Zai Lab Limited Unsponsored ADR has negative trailing earnings, so its P/E is not meaningful; Nurix Therapeutics, Inc. trades at 9.7×. Nurix Therapeutics, Inc. grew revenue faster over the last twelve months: 738.8% against 5.10%. Nurix Therapeutics, Inc. has the higher net margin (42.0% vs −41.9%) and the higher return on invested capital (0.00% vs −129.3%). Across the 18 metrics below, Nurix Therapeutics, Inc. leads on 16 and Zai Lab Limited Unsponsored ADR on 2.

Valuation

Metric NRIX ZLAB Biotechnology median
P/E 9.74 n/m 8.50
P/S 3.88 5.78 9.71
P/B 2.81 4.28 2.13
Price to free cash flow 7.37 n/m 20.82
EV/EBITDA 5.68 n/m 0.64
EV/Sales 2.39 4.71 9.21
Earnings yield 10.27% (7.35%) (33.15%)
Free cash flow yield 13.57% (6.25%) (25.50%)

Profitability

Metric NRIX ZLAB Biotechnology median
Gross margin 100.00% 56.47% 65.16%
Operating margin 41.27% (58.74%) 0.00%
Net margin 42.01% (41.86%) 0.00%
Free cash flow margin 52.68% (36.13%) 0.00%
Return on equity 43.99% (26.91%) (56.36%)
Return on assets 34.33% (16.81%) (48.04%)
Return on invested capital 0.00% (129.34%) 0.00%

Growth

Metric NRIX ZLAB Biotechnology median
Revenue growth (TTM) 738.76% 5.10% 6.02%
EPS growth (last fiscal year) (5.90%) 38.46% 30.26%
Revenue growth, 5-year CAGR 36.35% 56.54% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NRIX ZLAB Biotechnology median
Debt to equity 0.00 0.39 0.00
Current ratio 8.44 2.13 4.72
Net debt to EBITDA 2.14 2.66 0.96

Dividend

Metric NRIX ZLAB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NRIX ZLAB Biotechnology median
Market cap 2.73b 2.65b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack